MiMedx GroupMDXG +1.15%57 Net Current Asset Value is $1.17 as of Mar. 2026, which is 92% below its 10-year median of 15.24. GuruFocus rates MDXG with a GF Score™ of 57/100 and a GF Value™ of $6.89 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 946 Biotechnology companies, MiMedx Group ranks better than 63% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
MiMedx Group's net current asset value per share for the quarter that ended in Mar. 2026 was $1.17.
The historical rank and industry rank for MiMedx Group's Net Current Asset Value or its related term are showing as below:
MDXG'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 3.38 Med: 15.24 Max: 1261
Current: 3.38
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of MiMedx Group was 1261.00. The lowest was 3.38. And the median was 15.24.
MDXG's Price-to-Net-Current-Asset-Value is ranked better than 63% of 946
companies
in the Biotechnology industry
Industry Median: 4.955
vs MDXG: 3.38
MiMedx Group (NAS:MDXG) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
MiMedx Group Net Current Asset Value Related Terms
MiMedx Group Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for MiMedx Group's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MDXG vs MNPR, FTH, BBOT: Net Current Asset Value Comparison
For the Biotechnology subindustry, MiMedx Group's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MiMedx Group Price-to-Net-Current-Asset-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MiMedx Group's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where MiMedx Group's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of $1.17 mean?
MiMedx Group (MDXG) has a Net Current Asset Value of $1.17 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on MiMedx Group and its competitors. This is 92% below median its historical median of 15.24. Over the past decade, MiMedx Group's Net Current Asset Value has ranged from 3.38 to 1,261.00. According to the industry distribution chart, MiMedx Group ranks #350 out of 946 companies in the Biotechnology industry, placing it in the top 37%.
Is MiMedx Group's Net Current Asset Value too high?
MiMedx Group's current Net Current Asset Value of $1.17 is 92% below median its 10-year median of 15.24. Over the past 10 years, this metric has ranged from a low of 3.38 to a high of 1,261.00. The Biotechnology industry median Net Current Asset Value is 4.96. MiMedx Group's value of $1.17 is 76.4% below this industry median. Based on the distribution chart, MiMedx Group ranks #350 out of 946 companies in the Biotechnology industry, which is above the industry midpoint. Overall, MiMedx Group has a GF Score™ of 57/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does MiMedx Group's Net Current Asset Value compare to MNPR and FTH?
According to the Biotechnology industry distribution chart, MiMedx Group ranks #350 out of 946 companies for Net Current Asset Value. This puts MiMedx Group in the upper half of its industry. The industry median Net Current Asset Value is 4.96. MiMedx Group's value of $1.17 is 76.4% below this benchmark. Historically, MiMedx Group's own Net Current Asset Value has ranged from 3.38 to 1,261.00 over the past decade. While the company's 10-year median is 15.24 vs. the industry median of 4.96, MiMedx Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Biotechnology company?
The median Net Current Asset Value among Biotechnology companies is 4.96, based on 946 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MiMedx Group's current Net Current Asset Value of $1.17 is 76.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on MiMedx Group and its competitors. For the Biotechnology industry, the median Net Current Asset Value is 4.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MiMedx Group's current Net Current Asset Value is $1.17, which is 92% below median its own 10-year median of 15.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MiMedx Group stock overvalued right now?
Based on GuruFocus' analysis, MiMedx Group (MDXG) is currently considered Significantly Undervalued. The stock's GF Value™ is $6.89, compared to a current price of $3.95 — trading 42.7% below its estimated fair value. The current Net Current Asset Value is $1.17, which is 92% below median its 10-year median of 15.24 and 76.4% below the Biotechnology industry median of 4.96. MiMedx Group's overall GF Score™ is 57/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For MiMedx Group (MDXG), the current Net Current Asset Value is $1.17 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MiMedx Group (MDXG) Overvalued in 2026?
Based on GuruFocus' analysis, MiMedx Group stock appears to be undervalued.
The current stock price of $3.95 is trading 42.7% below its estimated GF Value™ of $6.89.
GuruFocus considers MiMedx Group to be Significantly Undervalued.
Key valuation signals for MDXG:
Net Current Asset Value: $1.17 (92% below median its 10-year median of 15.24)
GF Value™: $6.89 vs. price of $3.95 (42.7% below fair value)
Industry Position: 76.4% below the Biotechnology median (#350 of 946)
No single metric tells the full story. See the MDXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
57GF Score
Get the complete analysis for MDXG
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDXG has been successfully added to your 
